No products in the cart.
#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma
Click to read this study in the Journal of Clinical Oncology.
Tag: rituximab
Single dose of rituximab for new-onset myasthenia gravis associated with reduced risk of disease manifestations – The RINOMAX Randomized Clinical Trial
1. In this randomized clinical trial, among 47 individuals, the proportion with minimal myasthenia gravis (MG) manifestations with only low ...
Biosimilar drugs undergo rigorous clinical testing and yield comparable outcomes to biologics
1. Cancer biosimilar treatment trials have clinical outcomes that do not differ statistically from reference biologic products 2. The design ...
Belimumab after rituximab reduces risk for severe flare in systemic lupus erythematosus
1. Belimumab combined with rituximab was shown to significantly reduce IgG anti-dsDNA antibody levels in patients with systemic lupus erythematosus. ...
Rituximab increases sustained complete remission in patients with pemphigus vulgaris
1. A higher sustained complete remission rate was shown with rituximab treatment compared to mycophenolate mofetil in patients with pemphigus ...
Vemurafenib plus rituximab associated with complete response in refractory hairy-cell leukemia
1. Vemurafenib plus rituximab treatment was associated with complete response for refractory or relapsed hairy-cell leukemia patients. 2. Post hoc ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.